News

News

A Survey of siRNA Nanoscale Delivery Patents

by Christopher E. Loh; April M. Breyer Menon
March 24, 2014

Small interfering RNA (“siRNA”) therapy uses small molecules designed to pair with the sequence of messenger RNA that encodes disease-related proteins. The biotechnology industry has applied for and received hundreds of U.S. patents related to the nanoscale technologies to help with effective siRNA delivery. For example, Tekmira Pharmaceuticals has a patent portfolio for its lipidoid nanoparticle siRNA delivery technology, while Arrowhead Research has obtained patents covering its RONDEL platform of self-assembled siRNA-containing nanoparticles. This article summarizes some of the most visible siRNA delivery technologies and their patents in the current landscape.
This article originally appeared in volume 11, issue 1 of Nanotechnology Law & Business, www.nanolabweb.com. All rights reserved.

Download PDF

 

 

Christopher Loh has extensive experience counseling clients and litigating matters involving biotechnology and life sciences, including in the areas of antibody biosimilars, targeted cancer therapies, diabetes treatments and siRNA technologies. Christopher has a B.S. in Molecular Biochemistry and Biophysics and in Economics from Yale University.

    Methodology

    Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

    Disclaimer

    The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

    Subscribe for Future Updates

      captcha